TB Alliance is a not-for-profit product development partnership (PDP) committed to R&D that is urgently needed for better TB treatments. A Lack of commercial incentive for private sector investment in the development of products that target poverty related and neglected diseases like TB has resulted in a market deficit.
Building partnerships between the public, private, academic, and philanthropic sectors globally positions TB Alliance to harness the most promising science wherever it may exist around the world. Leveraging this global network of public and private partners, TB Alliance efficiently drives the development of new TB products for underserved markets. TB Alliance’s PDP model minimizes costs, including overhead and investments in infrastructure, while optimizing scientific capability to speed new TB drug development.
With over 15 years of experience in TB drug R&D and significant activities along the entire TB product development and commercialization value chain, TB Alliance has now assembled the largest TB drug portfolio in history.